Impact of alcohol cessation on liver health in patients with alcoholic hepatitis
Official title: Recompensation in Alcohol Related Hepatitis- A Prospective Cohort With Alcohol Cessation
Run by Copenhagen University Hospital, Hvidovre · NCT06740318 · Data updated 2026-11-12
This study tests how quitting alcohol can improve liver health in people with alcoholic hepatitis and sees if extra support helps them stop drinking.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Copenhagen University Hospital, Hvidovre Academic / other |
| Locations | 1 site (Hvidovre) |
| Status | Recruiting |
| Started | November 25, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | February 27, 2025 |
| Trial ID | NCT06740318 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with alcoholic hepatitis who are willing to participate in alcohol cessation interventions.
✕Probably not a fit
Patients with uncertain diagnoses of alcoholic hepatitis or those with hepatocellular carcinoma may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates how stopping alcohol consumption affects liver function and metabolism in patients diagnosed with alcoholic hepatitis. It aims to understand the biological mechanisms involved in recovery after alcohol cessation and the role of motivational enhancement therapy in supporting this process. Participants will be monitored from their diagnosis of alcoholic hepatitis, with assessments of metabolic changes in the liver and the effectiveness of therapeutic interventions. The study includes standard care alongside motivational support to encourage alcohol cessation.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with alcoholic hepatitis, enhancing liver recovery and overall health outcomes.
How similar studies have gone: Previous studies have shown promise in using motivational enhancement therapy for alcohol cessation, suggesting potential success for this approach in the context of alcoholic hepatitis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical suspicion of AH, supported by biochemistry (bilirubin 50 mmol/l or higher) and ultrasound or other imaging techniques. * Informed written consent. Exclusion Criteria: * People where the diagnosis of AH is questioned with reasonable doubt. * Withdrawal of informed consent. * Persons eligible for inclusion where the investigational program is delayed or not initiated within two months after the diagnosis of suspected AH. * Persons with hepatocellular carcinoma
Where it's running
-
University Hospital Hvidovre
Hvidovre, Denmark Recruiting
Study contacts
- Study coordinator: Nina Kimer, MD, PhD
- Email: nina.kimer@regionh.dk
- Phone: +4525140961
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.